Lung Ambition Alliance: Stronger Together 

Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Heather A. Wakelee, MD

The New WHO Classification of Lung Tumors

Patient Advocate Comment: Amivantamab for Exon 20

Comparing Patient-Reported Outcomes in the CROWN Study

Cultural Perceptions of End-of-Life Communication

Hereditary Predisposition Plays a Larger Role in SCLC Development Than Previously Recognized and May Inform Personalized Treatment

Presidential Symposium Findings 

ADAURA: Data is Only Part of the Story

Patient Comment on Mobocertinib for Exon 20

Improved Screening Uptake Could Help Double Lung Cancer Survival by 2025